A woman with mycosis fungoides, vitiligo, and a new hand nodule.
eccrine
mycosis fungoides
skin cancer
skin of color (SOC)
vitiligo
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
revised:
08
10
2024
received:
23
08
2024
accepted:
11
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
A 70-year-old African American female with a history of stage IV mycosis fungoides in remission presented with a gradually enlarging, red, ulcerated nodule on her right dorsal hand. The lesion was biopsied, and it showed intraepidermal proliferation with cytologic atypia and increased vasculature in the papillary dermis. Immunohistochemical staining indicated a yes-associated protein 1 (YAP1) rearrangement, confirmed by RNA sequencing, revealing a YAP1::MAML2 (mastermind-like transcriptional coactivator 2) fusion. The lesion was diagnosed as an eccrine porocarcinoma (EPC). The occurrence of EPCs following radiotherapy or trauma has been documented. This case highlights the importance of considering EPCs in patients with extensive skin treatments and immunosuppression history.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2024 the International Society of Dermatology.
Références
Tsiogka A, Koumaki D, Kyriazopoulou M, Liopyris K, Stratigos A, Gregoriou S. Eccrine porocarcinoma: a review of the literature. Diagnostics (Basel). 2023;13(8):1431. https://doi.org/10.3390/diagnostics13081431
Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, et al. Recurrent YAP1‐MAML2 and YAP1‐NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129(9):3827–3832. https://doi.org/10.1172/JCI126185
Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta‐analysis of 453 cases. Ann Med Surg (Lond). 2017;20:74–79. https://doi.org/10.1016/j.amsu.2017.06.027
Russell‐Goldman E, Hornick JL, Hanna J. Utility of YAP1 and NUT immunohistochemistry in diagnosing porocarcinoma. J Cutan Pathol. 2021;48(3):403–410. https://doi.org/10.1111/cup.13924
Snow JT, Georgantzoglou N, Green DC, Parra O, LeBlanc RE, Yan S, et al. Molecular analysis of NUT‐positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions. J Cutan Pathol. 2022;49(10):850–858. https://doi.org/10.1111/cup.14265
Miyamoto K, Yanagi T, Maeda T, Ujiie H. Diagnosis and Management of Porocarcinoma. Cancers (Basel). 2022;14(21):5232. https://doi.org/10.3390/cancers14215232